MTOR and acute lymphoblastic leukemia: Inhibition of mTOR using everolimus, an antiproliferative agent, reduces the expression of HIF-1α, decreases the glycolytic rate, and partially restores the sensitivity of ALL cells to vincristine under co-culture and hypoxic conditions (Frolova et al., 2012).